Octreotide LAR in carcinoid: how to dose?

Pancreas. 2008 Oct;37(3):337-8; author reply 338-9. doi: 10.1097/MPA.0b013e31818adf4b.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / blood
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Carcinoid Tumor / drug therapy*
  • Carcinoid Tumor / metabolism
  • Dose-Response Relationship, Drug
  • Drug Monitoring
  • Humans
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / metabolism
  • Octreotide / adverse effects
  • Octreotide / blood
  • Octreotide / therapeutic use*
  • Receptors, Somatostatin / metabolism
  • Research Design
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Receptors, Somatostatin
  • somatostatin receptor 2
  • Octreotide